Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review

Market Focus

08/07

On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.

On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \"ADC+IO\" development strategy.

Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1105886813"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105886813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105886813?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105886813","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review","media":"Market Focus","content":"<p><p>On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.</p><p>On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.</p><p>Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.</p><p>On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.</p><p>Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1105886813","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105886813","pubTimestamp":1786069036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.On the news front, the company recently announced that its novel...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|SKB生物常规交易涨3.15%，双有效载荷ADC药物SKB565中期业绩审核前获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}